Rosacea Treatment (TCT + RecoSMA® on the MULTILINE™ Platform)

Rosacea is a chronic, trigger-driven vascular and inflammatory condition—not just a few visible vessels. LINLINE treats it with a two-pillar approach on the MULTILINE™ base unit:

TCT — Target Creation Technology® to reduce the vascular component (background redness and fine telangiectasias).
RecoSMA® to support regeneration, strengthen the skin, and calm the field that keeps flaring.

Used alone or together (often in the same visit), these methods target what you see and what drives it.

Why rosacea care is different from “regular” vascular laser

Rosacea involves diffuse erythema + fragile micro-networks + flushing—not just discrete lines.
Skin is reactive; dosing must be gentle, incremental, with strict visual endpoints.
It’s relapsing. You plan a course and maintenance, not a one-and-done session.

How each method works

TCT (Target Creation Technology®) — for redness and visible vessels

Two wavelengths (540/1079 nm) in a pulse-train sequence.
Step 1 creates a selective intravascular “target” inside the vessel; Step 2 coagulates only that target, keeping heat away from epidermal melanin.
On-table endpoint: vessel darkening (not instant disappearance). No pulse stacking, no frosting.

What patients notice: baseline redness gradually dims, fine vessels fade, and flares look less dramatic.

RecoSMA® — for field regeneration and flare control

Er:YAG emitter with SMA (Spatially Modulated Ablation) module creates thousands of ≤50 μm micro-beams.
Surface micro-events launch acoustic waves that stimulate non-thermal, deep micro-repair (dermal remodeling, improved microcirculation).
Designed to preserve the barrier, with short social downtime.

What patients notice: skin looks calmer and stronger over weeks; texture and tone improve; makeup sits better; flushing often becomes less persistent.

Same-session combination (when the clinician opts to combine)

TCT first on focal networks/erythema until you see darkening without frosting.
RecoSMA® next to the broader facial field for regenerative support.
Why this order: TCT benefits from a clear view of target vessels; RecoSMA® then adds field-level normalization without masking TCT endpoints.

What a visit is like (patient view)

TCT: brief warm tingling; vessels/areas treated darken and then fade over days–weeks. Avoid heat/steam for a few days; everyday SPF for 2 weeks.
RecoSMA®: usually no anaesthesia; expect several social days of bronzing/micro-dots, then shedding; improvements accumulate for 1–3 months.

Back to life: most daily activities resume right away (RecoSMA® may warrant a few “camera-off” days).

Practitioner essentials (quick protocol logic)

TCT
- Emitter: Nd:YAP/KTP 1079/540 nm (Q-switched pulse trains).
- Frequency: ≤3 Hz on face; no overlap; treat smallest vessels first.
- Endpoint: darkening yes, frosting no. Intervals commonly 2–3 weeks.
RecoSMA®
- Emitter: Er:YAG 2.94 μm + SMA module; micro-spot ≤50 μm, high-density patterns.
- Barrier-sparing; plan densities/coverage by phototype, reactivity, and downtime tolerance.

Results & course planning

Course, not a one-off: initial series, then maintenance (rosacea is chronic).
TCT: visible reduction in background redness and vessel burden across the course.
RecoSMA®: progressive improvements in texture, tone, and “resilience.”
Timing is individualized; your clinician will set spacing based on reactivity, season, and goals.

Safety & aftercare (highlights)

Sun discipline matters: even with skin-sparing methods, use daily broad-spectrum SPF; avoid saunas/steam/hot baths for ~1 week after TCT.
Sensitive skin routines: gentle cleanser, non-fragranced barrier care; avoid known triggers (very hot drinks, spicy food, harsh actives) around treatment days.

Who is a good candidate?

Adults with persistent facial redness, flushing, visible fine vessels, and sensitive/reactive skin. RecoSMA® is especially helpful when rosacea coexists with texture changes or early post-inflammatory marks.

Benefits at a glance

For patients

Redness down, skin strength up: TCT reduces vascular visibility; RecoSMA® improves how your skin looks and behaves.
Natural results, minimal downtime: predictable recovery, barrier-friendly approach.
Customizable: combine in one visit or stage over time; plan for maintenance to stay ahead of flares.

For practitioners

Two precise tools tailored to rosacea’s dual nature (vascular + inflammatory).
Clear endpoints (TCT darkening; RecoSMA® densities) and preset programs for reproducible outcomes.
Platform simplicity: swap emitters on the MULTILINE™ base unit; add pigment care later if PIH appears.

Key takeaway

Rosacea needs more than “basic vascular laser.” LINLINE’s TCT + RecoSMA® strategy addresses both the visible vessels and the reactive, inflamed field—delivering calmer color, fewer visible nets, and sturdier skin over time, with a plan you can maintain.